Astatine-211: production and availability.
Astatine-211: production and availability.
复制标题
DOI：
10.2174/1874471011104030177
复制
发表时间：
2011-07
影响因子：
2.3
通讯作者：
Pruszynski M
中科院分区：
文献类型：
--
作者：
Zalutsky MR;Pruszynski M
半衰期为7.2小时的放射性卤素211 At为靶向α粒子治疗提供了许多潜在的优势;然而，由于其有限的可用性，其用于此目的受到限制。利用天然铋靶，通过~（209）Bi（α，2n）~（211）At核反应，可以用简单的方法以合理的产率制备~（211）Astatine。对于最大化211 At产量同时最小化210 At产量的最佳入射α粒子能量存在一些争论，这是有问题的，因为它的半衰期为138.4天的α粒子发射子体210 Po。生产211 At的内在成本相当适中，与商业上可获得的123 I相当。211 At的主要障碍是需要一个中等能量的α粒子束来生产。另一方面，世界上大约有30台回旋加速器具有生产211 At所需的束流特性。
The 7.2-h half life radiohalogen 211At offers many potential advantages for targeted α-particle therapy; however, its use for this purpose is constrained by its limited availability. Astatine-211 can be produced in reasonable yield from natural bismuth targets via the 209Bi( α,2n)211At nuclear reaction utilizing straightforward methods. There is some debate as to the best incident α-particle energy for maximizing 211At production while minimizing production of 210At, which is problematic because of its 138.4-day half life α-particle emitting daughter, 210Po. The intrinsic cost for producing 211At is reasonably modest and comparable to that of commercially available 123I. The major impediment to 211At availability is attributed to the need for a medium energy α-particle beam for its production. On the other hand, there are about 30 cyclotrons in the world that have the beam characteristics required for 211At production.